AbbVie (NYSE: ABBV) has updated its 2026 earnings guidance to reflect $216 million in pre-tax acquired in-process research and development (IPR&D) and milestones expense incurred during the third quarter of 2026.

The charge is expected to reduce both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share by $0.11 for the quarter ended September 30, 2026. The company noted that results for that period have not been finalized and remain subject to financial statement closing procedures.

Including the impact of the third-quarter IPR&D and milestones expense, AbbVie's full-year 2026 adjusted diluted earnings per share guidance range is $13.76 to $13.96. The updated third-quarter 2026 adjusted diluted earnings per share guidance range is $3.73 to $3.77.

AbbVie stated that it does not forecast acquired IPR&D and milestones expense due to uncertainty surrounding the timing and occurrence of collaborations, licensing agreements, and other asset acquisitions. The company's prior full-year guidance, issued July 31, 2026, had excluded the impact of any such expenses beyond the second quarter of 2026.